Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. Zoetis (ZTS) downgraded to Neutral from Buy at Citi by analyst Liav Abraham, who cited valuation, as she views the stock as fairly valued at current levels. The stock has significantly outperformed the specialty pharma group year-to-date, Abraham said, adding that she remains constructive on the company's fundamentals. The analyst increased her price target for shares to $50 from $46. 2. AbbVie (ABBV) downgraded to Market Perform from Outperform by BMO Capital, which cut its target on shares to $66 from $70. In the wake of events at ASCO, disclosures at AbbVie's R&D day, and statements from Eli Lilly (LLY) and Pfizer (PFE), the firm is more concerned about the longer term outlook for AbbVie's immunology franchise, especially Humira. 3. AmeriGas (APU) downgraded to Sell from Neutral at UBS by analyst Shneur Gershuni, who said the stock looks relatively expensive at current levels and that its yield is lower than competitors. The analyst, who kept a $39 price target on shares, also downgraded Ferrellgas Partners (FGP) to Sell and Suburban Propane (SPH) to Neutral. 4. J.M. Smucker (SJM) downgraded to Hold from Buy at Jefferies by analyst Akshay Jagdale, who raised his price target for shares to $143 from $140. The analyst views the stock's risk/reward as balanced at current levels amid rising commodity costs and the management transition. 5. Mattress Firm (MFRM) downgraded to Market Perform from Outperform at Raymond James by analyst Budd Bugatch following the Q1 report and conference call. The analyst said the Sleepy's integration, a move to a new corporate headquarters, and merchandising push to more proprietary products have increased near-term earnings risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Bullish option flow detected in Pfizer with 50,393 calls trading, 2x expected, and implied vol increasing over 2 points to 28.83%. Sep-24 27.5 calls and Mar-25 42.5 calls are the most active options, with total volume in those strikes near 27,600 contracts. The Put/Call Ratio is 0.21. Earnings are expected on May 1st.

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.

Barclays lowered the firm's price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.